Health-related quality of life in the era of erythropoietin

Hemodialysis International

Volumn 12, Issue 1, 2008, Pages 6-15

  Weisbord, Steven D ^a,b   Kimmel, Paul L ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Depression; Dialysis; Hematocrit; Hemoglobin; Mortality; Renal transplantation

Indexed keywords

HEMOGLOBIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; CARNITINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANEMIA; CLINICAL TRIAL; FATIGUE; FUNCTIONAL STATUS; HEMATOCRIT; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MAINTENANCE THERAPY; MORBIDITY; MORTALITY; PROGNOSIS; PSYCHOMETRY; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SOCIAL INTERACTION; SOCIAL SUPPORT; WELLBEING; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT TOOL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG WITHDRAWAL; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; KIDNEY TRANSPLANTATION; KINESIOTHERAPY; PHYSICAL CAPACITY; PSYCHOLOGICAL WELL BEING; QUESTIONNAIRE; REHABILITATION CARE; RENAL REPLACEMENT THERAPY; WEAKNESS;

ANEMIA; ERYTHROPOIETIN; FATIGUE; HEALTH STATUS; HUMANS; KIDNEY FAILURE, CHRONIC; QUALITY OF LIFE; RENAL DIALYSIS;

EID: 39049160503     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2008.00233.x     Document Type: Review

References (62)

1. Evans RW, Manninen DL, Garrison LP Jr, et al. The quality of life of patients with end-stage renal disease. N Engl J Med. 1985; 312: 553-559.
2. Johnson JP, McCauley CR, Copley JB. The quality of life of hemodialysis and transplant patients. Kidney Int. 1982; 22: 286-291.
3. Kimmel PL. Just whose quality of life is it anyway? Controversies and consistencies in measurements of quality of life. Kidney Int. 2000; 57: S113-S120.
4. Kimmel PL, Peterson RA, Weihs KL, et al. Aspects of quality of life in hemodialysis patients. J Am Soc Nephrol. 1995; 6: 1418-1426.
5. Kimmel PL, Peterson RA, Weihs KL, et al. Psychologic functioning, quality of life, and behavioral compliance in patients beginning hemodialysis. J Am Soc Nephrol. 1996; 7: 2152-2159.
6. Parfrey PS, Vavasour H, Bullock M, Henry S, Harnett JD, Gault MH. Symptoms in end-stage renal disease: Dialysis v transplantation. Transplant Proc. 1987; 19: 3407-3409.
7. Simmons RG, Abress L. Quality-of-life issues for end-stage renal disease patients. Am J Kidney Dis. 1990; 15: 201-208.
8. Simmons RG, Anderson C, Kamstra L. Comparison of quality of life of patients on continuous ambulatory peritoneal dialysis, hemodialysis, and after transplantation. Am J Kidney Dis. 1984; 4: 253-255.
9. Kimmel PL, Thamer M, Richard CM, Ray NF. Psychiatric illness in patients with end-stage renal disease. Am J Med. 1998; 105: 214-221.
10. Sacks CR, Peterson RA, Kimmel PL. Perception of illness and depression in chronic renal disease. Am J Kidney Dis. 1990; 15: 31-39.
11. Unruh M, Benz R, Greene T, et al. Effects of hemodialysis dose and membrane flux on health-related quality of life in the HEMO Study. Kidney Int. 2004; 66: 355-366.
12. Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002; 347: 2010-2019.
13. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 353: 238-248.
14. Mapes DL, Lopes AA, Satayathum S, et al. Health-related quality of life as a predictor of mortality and hospitalization: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int. 2003; 64: 339-349.
15. Bouleware LE, Liu Y, Fink NE, et al. The temporal relation between depression symptoms, cardiovascular disease events and mortality in ESRD: Contribution of reverse causality. Clin J Am Soc Nephrol. 2006; 1: 496-504.
16. Kimmel PL. Psychosocial factors in adult end-stage renal disease patients treated with hemodialysis: Correlates and outcomes. Am J Kidney Dis. 2000; 35: S132-S140.
17. Kimmel PL. Depression in patients with chronic renal disease: What we know and what we need to know. J Psychosom Res. 2002; 53: 951-956.
18. Kimmel PL, Peterson RA, Weihs KL, et al. Multiple measurements of depression predict mortality in a longitudinal study of chronic hemodialysis outpatients. Kidney Int. 2000; 57: 2093-2098.
19. Beusterien KM, Nissenson AR, Port FK, Kelly M, Steinwald B, Ware JE Jr. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol. 1996; 7: 763-773.
20. Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, Jofre R, Valderrabano F. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol. 2000; 11: 335-342.
21. Nissenson AR. Epoetin and cognitive function. Am J Kidney Dis. 1992; 20: 21-24.
22. Robertson HT, Haley NR, Guthrie M, Cardenas D, Eschbach JW, Adamson JW. Recombinant erythropoietin improves exercise capacity in anemic hemodialysis patients. Am J Kidney Dis. 1990; 15: 325-332.
23. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998; 339: 584-590.
24. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006; 355: 2071-2084.
25. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355: 2085-2098.
26. Cukor D, Cohen SD, Peterson RA, Kimmel PL. Psychosocial aspects of chronic disease: ESRD as a paradigmatic illness. J Am Soc Nephrol. 2007; 12: 3042-3055.
27. Unruh ML, Weisbord SD, Kimmel PL. Health-related quality of life in nephrology research and clinical practice. Semin Dial. 2005; 18: 82-90.
28. Kutner NG. Assessing end-stage renal disease patients' functioning and well-being: Measurement approaches and implications for clinical practice. Am J Kidney Dis. 1994; 24: 321-333.
29. Edgell ET, Coons SJ, Carter WB, et al. A review of health-related quality-of-life measures used in end-stage renal disease. Clin Ther. 1996; 18: 887-938.
30. Kurtin PS, Davies AR, Meyer KB, DeGiacomo JM, Kantz ME. Patient-based health status measures in outpatient dialysis. Early experiences in developing an outcomes assessment program. Med Care. 1992; 30: MS136-MS149.
31. Meyer KB, Espindle DM, DeGiacomo JM, Jenuleson CS, Kurtin PS, Davies AR. Monitoring dialysis patients' health status. Am J Kidney Dis. 1994; 24: 267-279.
32. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The sickness impact profile: Development and final revision of a health status measure. Med Care. 1981; 19: 787-805. 19
33. Bergner M, Bobbitt RA, Kressel S, Pollard WE, Gilson BS, Morris JR. The Sickness Impact Profile: Conceptual formulation and methodology for the development of a health status measure. Int J Health Serv. 1976; 6: 393-415.
34. Bergner M, Bobbitt RA, Pollard WE, Martin DP, Gilson BS. The Sickness Impact Profile: Validation of a health status measure. Med Care. 1976; 14: 57-67.
35. Mor V, Laliberte L, Morris JN, Wiemann M. The Karnofsky performance status scale. An examination of its reliability and validity in a research setting. Cancer. 1984; 53: 2002-2007.
36. Hays RD, Kallich JD, Mapes DL, Coons SJ, Carter WB. Development of the Kidney Disease Quality of Life (KDQOL) instrument. Qual Life Res. 1994; 3: 329-338.
37. Korevaar JC, Merkus MP, Jansen MA, Dekker FW, Boeschoten EW, Krediet RT. Validation of the KDQOL-SF: A dialysis-targeted health measure. Qual Life Res. 2002; 11: 437-447.
38. Wu AW, Fink NE, Cagney KA, et al. Developing a health-related quality-of-life measure for end-stage renal disease: The CHOICE health experience questionnaire. Am J Kidney Dis. 2001; 37: 11-21.
39. Kimmel PL, Emont SL, Newmann JM, Danko H, Moss AH. ESRD patient quality of life: Symptoms, spiritual beliefs, psychosocial factors, and ethnicity. Am J Kidney Dis. 2003; 42: 713-721.
40. Merkus MP, Jager KJ, Dekker FW, de Haan RJ, Boeschoten EW, Krediet RT. Physical symptoms and quality of life in patients on chronic dialysis: Results of The Netherlands Cooperative Study on Adequacy of Dialysis (NECOSAD). Nephrol Dial Transplant. 1999; 14: 1163-1170.
41. Weisbord SD, Fried LF, Arnold RM, et al. Prevalence, severity, and importance of physical and emotional symptoms in chronic hemodialysis patients. J Am Soc Nephrol. 2005; 16: 2487-2494.
42. Patel SS, Shah VS, Peterson RA, Kimmel PL. Psychosocial variables, quality of life, and religious beliefs in ESRD patients treated with hemodialysis. Am J Kidney Dis. 2002; 40: 1013-1022.
43. Tawney KW, Tawney PJ, Hladik G, et al. The life readiness program: A physical rehabilitation program for patients on hemodialysis. Am J Kidney Dis. 2000; 36: 581-591.
44. DePaul V, Moreland J, Eager T, Clase CM. The effectiveness of aerobic and muscle strength training in patients receiving hemodialysis and EPO: A randomized controlled trial. Am J Kidney Dis. 2002; 40: 1219-1229.
45. Heidenheim AP, Muirhead N, Moist L, Lindsay RM. Patient quality of life on quotidian hemodialysis. Am J Kidney Dis. 2003; 42: 36-41.
46. Kooistra MP, Vos J, Koomans HA, Vos PF. Daily home haemodialysis in The Netherlands: Effects on metabolic control, haemodynamics, and quality of life. Nephrol Dial Transplant. 1998; 13: 2853-2860.
47. Kurella M, Suri RS, Chertow GM. Frequent hemodialysis and psychosocial function. Semin Dial. 2005; 18: 132-136.
48. Ting GO, Kjellstrand C, Freitas T, Carrie BJ, Zarghamee S. Long-term study of high-comorbidity ESRD patients converted from conventional to short daily hemodialysis. Am J Kidney Dis. 2003; 42: 1020-1035.
49. Taji Y, Morimoto T, Fukuhara S, Fukui T, Kuwahara T. Effects of low dialysate calcium concentration on health-related quality of life in hemodialysis patients. Clin Exp Nephrol. 2005; 9: 153-157.
50. Sloan RS, Kastan B, Rice SI, et al. Quality of life during and between hemodialysis treatments: Role of L-carnitine supplementation. Am J Kidney Dis. 1998; 32: 265-272.
51. Rathod R, Baig MS, Khandelwal PN, Kulkarni SG, Gade PR, Siddiqui S. Results of a single blind, randomized, placebo-controlled clinical trial to study the effect of intravenous L-carnitine supplementation on health-related quality of life in Indian patients on maintenance hemodialysis. Indian J Med Sci. 2006; 60: 143-153.
52. Brass EP, Adler S, Sietsema KE, Hiatt WR, Orlando AM, Amato A. Intravenous L-carnitine increases plasma carnitine, reduces fatigue, and may preserve exercise capacity in hemodialysis patients. Am J Kidney Dis. 2001; 37: 1018-1028.
53. Fishbane S. Anemia treatment in chronic renal insufficiency. Semin Nephrol. 2002; 22: 474-478.
54. Fishbane S. Recombinant human erythropoietin: Has treatment reached its full potential? Semin Dial. 2006; 19: 1-4.
55. Nissenson AR. Recombinant human erythropoietin: Impact on brain and cognitive function, exercise tolerance, sexual potency, and quality of life. Semin Nephrol. 1989; 9: 25-31.
56. Evans RW, Rader B, Manninen DL. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group. JAMA. 1990; 263: 825-830.
57. Levin NW, Lazarus JM, Nissenson AR. National Cooperative rHu Erythropoietin Study in patients with Chronic Renal Failure - an interim report. The National Cooperative rHu Erythropoietin Study Group. Am J Kidney Dis. 1993; 22: 3-12.
58. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group. BMJ. 1990; 300: 573-578.
59. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol. 2005; 16: 2180-2189.
60. Furuland H, Linde T, Ahlmen J, Christensson A, Strombom U, Danielson BG. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant. 2003; 18: 353-361.
61. Ritz E, Laville M, Bilous RW, et al. Target level for hemoglobin correction in patients with diabetes and CKD: Primary results of the Anemia Correction in Diabetes (ACORD) study. Am J Kidney Dis. 2007; 49: 194-207.
62. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: A meta-analysis. Lancet. 2007; 369: 381-388.